Artrya (ASX:AYA) Treasury Stock : A$0.00 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Artrya Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Artrya's treasury stock for the quarter that ended in Dec. 2024 was A$0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Artrya Treasury Stock Historical Data

The historical data trend for Artrya's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artrya Treasury Stock Chart

Artrya Annual Data

Trend

Jun21

Jun22

Jun23

Jun24

Treasury Stock

Artrya Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Treasury Stock	Get a 7-Day Free Trial			-	-	-	-	-

Artrya Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Artrya Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Artrya Ltd (ASX:AYA) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

1257 Hay Street, West Perth, Perth, WA, AUS, 6005

Website

https://www.artrya.com

Artrya Ltd is a medical technology company. It is engaged in the development and commercialization of Artrya Salix, its patented artificial intelligence platform that detects, diagnoses, and helps address coronary artery disease. The company is managed based on a single segment, being the development of AI-driven CCTA image analysis technology.

Artrya Headlines

No Headlines